AstraZeneca to increase external R&D
This article was originally published in Scrip
Executive Summary
AstraZeneca will be increasing its collaborative activities with the not-for-profit organisation Medicines for Malaria Venture (MMV), revealed Dr Anders Ekblom, AstraZeneca's vice-president of global medicines development, at the BioPartnering Europe meeting recently.